Roche Holding AG (ROG.SW)
Swiss - Swiss Delayed price. Currency in CHF
Add to watchlist
At close: 05:30PM CEST
| Previous close | 234.80 |
| Open | 235.10 |
| Bid | 237.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 234.00 - 237.80 |
| 52-week range | 212.90 - 293.55 |
| Volume | |
| Avg. volume | 1,467,699 |
| Market cap | 191.396B |
| Beta (5Y monthly) | 0.16 |
| PE ratio (TTM) | 16.58 |
| EPS (TTM) | 14.30 |
| Earnings date | 25 Jul 2024 |
| Forward dividend & yield | 9.60 (4.09%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | 273.94 |
Zacks4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
Barrons.comDow Hitting 40,000 Is Good but Look Here for Where Markets Are Headed, and 5 Other Things to Know Today.
Reddit content is coming to OpenAI’s chatbot, Roche’s weight-loss drug impresses analysts in early-stage trials, and other news to start your day.
Barrons.comRoche’s New Weight-Loss Data Shows Lilly Isn’t Unbeatable in Obesity
The results, from a small trial of a drug called CT-388, hint that Roche could be a serious player in the weight-loss market in coming years.
© 2024 Yahoo. All rights reserved.